ESR1 and breast carcinoma: These findings consistently demonstrate how the role of RUNX1 is dependent on the subtype of breast cancer (ER+ vs. ER-) and that the effect of RUNX1 on tumor cells depends on the context under which it is expressed (Figure 3).